Sociedad Americana de Hirudoterapia

Construction of Corynebacterium glutamicum for efficient secretion and production of recombinant proteins using the technology of ARTP mutagenesis and fluorescen activated droplet microfluidic screening

Research article published in Bioresource technology (2026)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: In vitro / laboratoryGenómica y proteómicaResistencia antimicrobianaDesarrollo de fármacosFarmacología salivalLiu X et al. · Bioresource technology, 2026

Abstract

In order to increase the secretion and expression of Corynebacterium glutamicum (C. glutamicum) as microbial cell factory, Actinobacillus porcine pleuropneumoniae outer membrane protein 7 (Omp7) was used as the target protein and a total of four mutant strains with efficient secretion and expression including CT1-109, CT2-9, CT3-28 and CT4-42 were obtained by the four rounds of Atmospheric and Room Temperature Plasma (ARTP) mutagenesis and fluorescence-activated droplet sorting (FADS) technology. The mutant strain CT3-28 was verificated and showed the highest fluorescence value after mutagenesis saturation. Four recombinant proteins including Actinobacillus pleuropneumonia RTX, procollagen type I N-terminal peptide, hirudin variants III and variable domain of heavy chin of heavy-chin antibody, were expressed in CT1, CT2 and CT3 strains, respectively. The results showed that the mutant strains were able to increase the secreted expression of other recombinant proteins. The amplified fermentation experiment of the mutant strain CT3-28 was performed by using a 5 L fermenter with fed-batch, and the yield of Omp7 was about 211.3 mg·L-1, which was 82.6% higher than that of WT. A total of 91 single-nucleotide polymorphisms (SNPs) were identified by resequencing the genomes of C. glutamicum CGMCC1.15647 and the mutagenized strains CT1, CT2, and CT3, of which the optimal strain CT3 included four related genes. Further overexpression and knockout of the SNP genes indicated that the genes RS02840 and RS02495 had a significant effect on the secretory expression of recombinant proteins, and provides target genes and strategies for modifying chassis cells to increase secretion expression in subsequent studies.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsCorynebacterium glutamicumRecombinant ProteinsMutagenesisMicrofluidicsFermentationFluorescenceMutation

Resumen

In order to increase the secretion and expression of Corynebacterium glutamicum (C.

Por qué esto importa para la hirudoterapia

This biotechnology study describes the use of Atmospheric and Room Temperature Plasma (ARTP) mutagenesis and fluorescence-activated droplet sorting to construct mutant strains of Corynebacterium glutamicum with enhanced secretion and expression of recombinant proteins, including hirudin variants III among four test proteins. The abstract does not provide context on hirudin's biological origin or its relationship to leeches. The study's potential relevance to hirudotherapy is limited to the incidental inclusion of a hirudin variant among several recombinant proteins used to validate the secretion platform. It does not involve live leeches, leech extracts, or clinical applications of hirudotherapy.

Citación

Construction of Corynebacterium glutamicum for efficient secretion and production of recombinant proteins using the technology of ARTP mutagenesis and fluorescen activated droplet microfluidic screening

Liu X et al. · Bioresource technology, 2026

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.